No profile data available.
Acrivon Therapeutics, Inc. (ACRV) is a healthcare company in the additional cancer treatment drugs industry, based in Watertown, United States, with about 74 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$77.91 million. Its market capitalization was $81.85 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Acrivon Therapeutics reported $0 in revenue for fiscal year 2025.
$81.85 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include PDS Biotechnology Corporation (PDSB), OnKure Therapeutics, Inc. (OKUR), Context Therapeutics Inc. (CNTX), NeOnc Technologies Holdings, Inc. (NTHI).